EMBARGOED FOR RELEASE: 3 P.M. (CT), WEDNESDAY, JANUARY 30, 2013
JAMA Psychiatry Study Highlights
Study Examines Response to Scopolamine in Major Depressive Disorder
Maura L. Furey, Ph.D., of the National Institute of Mental Health, National Institutes of Health, Bethesda, Md., and colleagues conducted a double-blind, placebo-controlled, crossover study together with repeated functional magnetic resonance imaging to determine if baseline brain activity when processing emotional information can predict treatment response to scopolamine in major depressive disorder (MDD).
The need for improved treatment options for patients with MDD is critical, according to the study authors. Scopolamine produces rapid antidepressant effects and offers the opportunity to characterize potential biomarkers of treatment response within short periods.
The study included 15 currently depressed outpatients who met the criteria for recurrent MDD and 21 healthy participants between the ages of 18 and 55 years. Imaging was acquired as participants performed face-identity and face-emotion working memory tasks.
“These results implicate cholinergic and visual processing dysfunction in the pathophysiology of MDD and suggest that neural response in the visual cortex, selectively to emotional stimuli, may provide a useful biomarker for identifying patients who will respond favorably to scopolamine,” the study concludes. (Online First)
(JAMA Psychiatry. Published online January 30, 2013. doi:10.1001/2013.jamapsychiatry.60. Available pre-embargo to the media at http://media.jamanetwork.com.)
Editor’s Note: Authors made conflict of interest disclosures. This research was supported by the National Institutes of Health National Institute of Mental Health Division of Intramural Research Programs. Please see the articles for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
# # #
For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email email@example.com.